OrbiMed’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-3,436,332
Closed -$29.8M 135
2018
Q4
$29.8M Sell
3,436,332
-61,193
-2% -$702K 0.55% 56
2018
Q3
$54.1M Hold
3,497,525
0.65% 46
2018
Q2
$56M Hold
3,497,525
0.67% 46
2018
Q1
$45.2M Sell
3,497,525
-1,905,564
-35% -$23.7M 0.56% 53
2017
Q4
$67.8M Sell
5,403,089
-1,473,396
-21% -$19.2M 0.86% 39
2017
Q3
$90.8M Hold
6,876,485
0.87% 35
2017
Q2
$109M Sell
6,876,485
-1,769,627
-20% -$25.7M 1.14% 26
2017
Q1
$124M Hold
8,646,112
1.4% 22
2016
Q4
$111M Sell
8,646,112
-3,232,994
-27% -$40.8M 1.41% 25
2016
Q3
$158M Hold
11,879,106
1.8% 18
2016
Q2
$130M Sell
11,879,106
-1,912,072
-14% -$18.7M 1.36% 24
2016
Q1
$126M Buy
13,791,178
+386,856
+3% +$3.19M 1.33% 26
2015
Q4
$130M Hold
13,404,322
1.18% 30
2015
Q3
$117M Sell
13,404,322
-1,404,263
-9% -$13.1M 1.18% 28
2015
Q2
$150M Buy
14,808,585
+466,138
+3% +$5.42M 1.25% 26
2015
Q1
$192M Hold
14,342,447
1.64% 24
2014
Q4
$184M Hold
14,342,447
1.76% 24
2014
Q3
$156M Buy
14,342,447
+3,672,982
+34% +$42M 1.63% 24
2014
Q2
$137M Buy
10,669,465
+9,377,438
+726% +$102M 1.61% 25
2014
Q1
$13.3M Buy
+1,292,027
New +$14.5M 0.16% 75

Other funds holding IRWD

OrbiMed's IRWD Position: Q1 2019 in Review

OrbiMed sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2019, closing a stake of 3,436,332 shares — an estimated $29.8M sold.

OrbiMed first reported a position in IRWD in Q1 2014 and held it in 20 quarters. The position peaked at $192M in Q1 2015. 156 funds tracked by Wall St. Rank hold IRWD as of Q1 2019.

  • OrbiMed reported no remaining Ironwood Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • OrbiMed sold 3,436,332 Ironwood Pharmaceuticals shares in Q1 2019, an estimated $29.8M.
  • OrbiMed first reported a position in Ironwood Pharmaceuticals in Q1 2014 and held it in 20 quarters.
  • OrbiMed's Ironwood Pharmaceuticals position peaked at $192M in Q1 2015.
  • 156 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.